2014
DOI: 10.1038/507418a
|View full text |Cite
|
Sign up to set email alerts
|

Immunology: A tolerant approach

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
25
0
1

Year Published

2015
2015
2019
2019

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 26 publications
(26 citation statements)
references
References 12 publications
0
25
0
1
Order By: Relevance
“…A ntigen-specific tolerance could be a way of controlling autoimmune diseases and allergy without broad immune suppression (1). IFN-a can inhibit Ag-specific proliferation and prevent inflammation (2,3), but its direct usage is hampered by proinflammatory properties, for example, as those observed in systemic lupus erythematosus and myositis (4).…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…A ntigen-specific tolerance could be a way of controlling autoimmune diseases and allergy without broad immune suppression (1). IFN-a can inhibit Ag-specific proliferation and prevent inflammation (2,3), but its direct usage is hampered by proinflammatory properties, for example, as those observed in systemic lupus erythematosus and myositis (4).…”
mentioning
confidence: 99%
“…This 28-d arthritis model consists of a sensitization phase (days [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20], in which Ag-specific immunity develops, and an effector phase (days 21-28) triggered by intraarticular Ag rechallenge. To prevent development of arthritis, type I IFN signaling must be activated during sensitization, because the same regimen of IFN-a treatment given at the onset of the effector phase has no protective effect.…”
mentioning
confidence: 99%
“…However, despite efforts for several decades in multiple indications, progress has been slow and, in some cases, there has been disease exacerbation 39. Principal stumbling blocks have included determination of the therapeutic dose (there is evidence that the dose response may be U shaped), formulation, inclusion of adjuvants (and if so, type of adjuvant), route of administration, and dosing frequency.…”
Section: Targets For Immune Interventionmentioning
confidence: 99%
“…RA being an autoimmune disease, induction of immune-tolerance against arthritogenic antigen would be the ideal strategy for controlling RA. This strategy can leave the immune system intact to fight against infectious agents or any other dangers, while at the same time preventing immune attacks against arthritogenic antigens (Garber, 2014 Carter, 2009, Burmester et al, 2014). However, the cellular microenvironment consisting of cytokines, chemokines and other protein/non-protein immune mediators, is crucial for these cells to exhibit tolerogenic properties.…”
Section: Immune-tolerance Approach For Ra Patientsmentioning
confidence: 99%